Adnan M. M. Mjalli - Oak Ridge NC, US Ye Edward Tian - Jamestown NC, US Jeffrey C. Webster - Jamestown NC, US Robert Rothlein - Summerfield NC, US
Assignee:
Transtech Pharma, Inc. - High Point NC
International Classification:
A61K 39/00 C12P 21/00 A61K 38/16
US Classification:
4241781, 5303873, 530402
Abstract:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
Adnan M. M. Mjalli - Oak Ridge NC, US Ye E. Tian - Jamestown NC, US Jeffrey C. Webster - Jamestown NC, US Robert Rothlein - Summerfield NC, US
Assignee:
Transtech Pharma, Inc. - High Point NC
International Classification:
A61K 39/00 C12P 21/00 A61K 38/16
US Classification:
4241781, 5303873, 530402, 514 11
Abstract:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
Rage Fusion Proteins, Formulations, And Methods Of Use Thereof
Adnan M. M. Mjalli - Oak Ridge NC, US Robert Rothlein - Summerfield NC, US Ye Edward Tian - Jamestown NC, US Jeffrey C. Webster - Jamestown NC, US Eric J. Benjamin - Jamestown NC, US
Assignee:
Transtech Pharma, Inc. - High Point NC
International Classification:
A61K 39/00 A61K 38/16 C12P 21/00
US Classification:
4241781, 5303873, 530402, 514 11
Abstract:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin C2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
Adnan M. M. Mjalli - Oak Ridge NC, US Robert Rothlein - Summerfield NC, US Ye Edward Tian - Jamestown NC, US Jeffrey C. Webster - Jamestown NC, US
Assignee:
TransTech Pharma, Inc. - High Point NC
International Classification:
C07H 21/04
US Classification:
536 234
Abstract:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to the N-terminus of an immunoglobulin C2 domain. Also disclosed are RAGE fusion protein formulations and the use of the RAGE fusion proteins and RAGE fusion protein formulations as therapeutics for RAGE-mediated pathologies.
Adnan Mjalli - Oak Ridge NC, US David Stern - Cincinnati OH, US Ye Tian - Jamestown NC, US Jeffrey Webster - Jamestown NC, US Robert Rothlein - Summerfield NC, US
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
Adnan Mjalli - Jamestown NC, US Jeffrey Webster - Jamestown NC, US
Assignee:
TRANSTECH PHARMA, INC. - HIGH POINT NC PFIZER INC. - NEW YORK NY
International Classification:
G01N 33/567 C12M 1/34
US Classification:
435007200, 435287200
Abstract:
Disclosed are methods and systems that use fluorescence polarization to identify compounds that have the ability to bind to, and/or modulate, the activity of the Receptor for Advanced Glycated Endproducts (RAGE). Compounds identified using the methods and systems of the present invention may comprise small organic molecule RAGE antagonists. The small organic molecule RAGE antagonists identified using the methods and systems of the present invention may be used to treat RAGE-mediated diseases, such as, but not limited to, diabetes or Alzheimer's disease.
Immunoglobulin Fusion Proteins And Methods Of Making
Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
Adnan M.M. Mjalli - Oak Ridge NC, US Jeffrey C. Webster - Jamestown NC, US Robert Rothlein - Summerfield NC, US Ye E. Tian - Jamestown NC, US
International Classification:
A61K 39/395 A61P 37/00
US Classification:
4241341
Abstract:
Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
Isbn (Books And Publications)
Critical Advances in Reminisence Work: From Theory to Application
Banner Medical Group Corporate CenterBanner Medical Group Orthopedic Clinic 801 E Williams Ave STE 3301, Fallon, NV 89406 7758677757 (phone), 7754238871 (fax)
Education:
Medical School Wayne State University School of Medicine Graduated: 1986
Procedures:
Arthrocentesis Carpal Tunnel Decompression Hip Replacement Hip/Femur Fractures and Dislocations Knee Arthroscopy Knee Replacement Lower Arm/Elbow/Wrist Fractures and Dislocations Lower Leg/Ankle Fractures and Dislocations Shoulder Arthroscopy Shoulder Surgery
Conditions:
Fractures, Dislocations, Derangement, and Sprains Internal Derangement of Knee Internal Derangement of Knee Cartilage Internal Derangement of Knee Ligaments Intervertebral Disc Degeneration
Languages:
English
Description:
Dr. Webster graduated from the Wayne State University School of Medicine in 1986. He works in Reno, NV and 1 other location and specializes in Orthopaedic Surgery. Dr. Webster is affiliated with Banner Churchill Community Hospital, Northern Nevada Medical Center, Renown Regional Medical Center and Saint Marys Reno Regional Medical Center.
This organization talks about and looks at youth education, diversity and racial reconciliation, and those are the same things Nissan looks at, said Jeffrey Webster, director of human resources for Nissan North America in Canton, near Jackson. He said the gift can be used however the institute see
Date: Apr 12, 2013
Category: U.S.
Source: Google
Youtube
Wisdom Research Forum: "The H.E.R.O.(E) Model...
"The H.E.R.O.(E) Model of Wisdom" Presentation by Instructor of Psycho...